HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Forms Nanotechnology Task Force To Assess Technology

This article was originally published in The Rose Sheet

Executive Summary

FDA's Nanotechnology Task Force will identify policy gaps related to the use of nanotechnology particles to evaluate possible adverse health effects from products that contain the materials, the agency said

You may also be interested in...



Nanotechnology Regulation Limited By FDA Budget Constraints – Report

FDA's budget constraints and gaps in its legal authority hinder its ability to understand and manage nanotechnology's potential risks, according to Michael Taylor, a professor at the University of Maryland School of Medicine who formerly served as deputy commissioner for policy at FDA

Nanotechnology Regulation Limited By FDA Budget Constraints – Report

FDA's budget constraints and gaps in its legal authority hinder its ability to understand and manage nanotechnology's potential risks, according to Michael Taylor, a professor at the University of Maryland School of Medicine who formerly served as deputy commissioner for policy at FDA

FDA nanotech meeting

Agency will sponsor public meeting in mid-October on nanotechnology, FDA announces in April 13 Federal Register notice. Topics slated to be discussed include types of nanotechnology material products under development in the areas of cosmetics, foods, drugs and other FDA-regulated areas. Meeting also provides opportunity to evaluate "whether there are scientific issues that should be addressed; and any other issues about which the regulated industry, academia and the interested public may wish to inform FDA" concerning nanotechnology use, FDA notes. Details regarding date and time of meeting, which will be held in Washington, D.C., will be provided in a subsequent Federal Register notice, agency adds...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel